What is TLX101-Px?
PET Imaging Agent: It uses a radioactive tracer called 18F-FET (floretyrosine F 18). A PET scan is a medical imaging test that highlights active disease in the body.
Target: It attaches to specific proteins on cells (LAT1 and LAT2) to spot cancer cells.
PDUFA and/or TLX101-Px InterestWhat Does It Do?
Detects Glioma: Glioma is a common type of malignant brain tumor.
Differentiates Changes: It helps doctors tell the difference between returning cancer and normal healing changes after radiation or chemotherapy.
Patient Care: It may work alongside a targeted therapy candidate called TLX101-Tx.
Current Status
FDA Review: The U.S. Food and Drug Administration (FDA) accepted a resubmitted New Drug Application (NDA) for the drug.
Timeline: The FDA set a target decision date (PDUFA date) of September 11, 2026.
Approval Status: It is not yet approved or available for commercial sale in any country.
Special Status: The FDA granted it Orphan Drug and Fast Track designations to speed up the review of treatments for rare and serious conditions.
What Is a PDUFA Date — and Why Does It Matter?
A PDUFA date is the target date established by the U.S. Food and Drug Administration (FDA) for completing its review of a new drug or medical product and determining whether it can be approved for use in the United States.
PDUFA stands for the Prescription Drug User Fee Act, which helps provide the FDA with resources to review new drug applications within established timelines.
For patients, caregivers, and healthcare providers, a PDUFA date can represent an important milestone — especially when the product under review could offer a new way to diagnose, monitor, or treat a serious disease.
Why PDUFA Dates Matter
A Milestone for Patients and Families
For people facing serious illnesses such as brain cancer, a PDUFA date provides a clearer timeline for when the FDA may make a decision about a promising new medical option.
The Final Stage of an Extensive Review Process
Before reaching this point, a product has typically undergone years of research, clinical studies, safety and effectiveness evaluation, manufacturing review, and regulatory assessment.
Greater Clarity for Patients and Healthcare Providers
Knowing the FDA's target decision date helps patients, clinicians, researchers, and advocates understand when an important regulatory milestone may occur.
What Happens on the PDUFA Date
By the PDUFA target date, September 11th, 2026, the FDA is expected to complete its review and may:
- Approve the application;
- Request additional information or requirements before approval; or
- Take another regulatory action that affects the review timeline.
A PDUFA date is therefore not a guaranteed approval date, but it is an important milestone for everyone following the development of a potentially meaningful new option for people affected by brain tumors.
